Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Επικοινωνία Submitted by Δημήτρης Σπάχος on Τρί, 10/02/2018 - 12:57
